FDA approves Taro's NDA for Topicort Topical Spray

Download PDF Copy

Apr 15 2013

NewsGuard 100/100 Score

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro") reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its New Drug Application ("NDA") Topicort^® (desoximetasone) Topical Spray, 0.25%.

Topicort^® (desoximetasone) Topical Spray, 0.25% is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older.

According to industry sources, the corticosteroid spray market is approximately $100 million in annual sales in the U.S.

SOURCE Taro Pharmaceutical Industries Ltd.

Posted in: Disease/Infection News | Pharmaceutical News

Tags: Corticosteroid, Food, New Drug Application, Pharmaceuticals, Psoriasis

Comments (0)

Download PDF Copy

Suggested Reading

Study shows how a single defective BRCA1 gene accelerates cancer development

Study shows how a single defective BRCA1 gene accelerates cancer development

Healthy lifestyle choices can offset genetic risk for brain diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

Study focuses on COPD progression in younger populations

Study focuses on COPD progression in younger populations

Antibiotic resistance threatens millions of lives worldwide

Antibiotic resistance threatens millions of lives worldwide

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Combination therapy shows promising results in treating stage 3 melanoma

Combination therapy shows promising results in treating stage 3 melanoma

New biomarkers offer hope for early detection and prevention of Alzheimer's

New biomarkers offer hope for early detection and prevention of Alzheimer's

Research links COVID-19 vaccines to temporary facial palsy in over 5,000 patients

Research links COVID-19 vaccines to temporary facial palsy in over 5,000 patients

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

New study links circadian gene variants to winter depression